GYG Gyg Plc

RNS Number:6706V
Gyrus Group PLC
9 May 2002

Embargoed for release, Thursday 9 May 2002 - 07.00am (BST)


GYRUS LAUNCHES PLASMA-SECTTM  LARGE LOOP FOR TREATMENT OF BENIGN PROSTATIC
HYPERPLASIA IN MEN



Reading, UK - Gyrus Group PLC (GYG.L "Gyrus" or "the Group"), a world leader in
the management of tissue using less traumatic techniques, has launched its new
Plasma-Sect Large Loop for the treatment of benign prostatic hyperplasia (BPH) a
condition that affects more than 15 million men worldwide.



The 4.0 mm device is designed to remove tissue during a procedure known as
transurethral resection of the prostate. The Plasma-Sect Large Loop works by
forming a plasma corona, which rapidly and consistently vaporizes excess tissue
that is pressing against the urethra.  This type of surgery relieves the
obstruction and incomplete bladder emptying caused by BPH.



The Plasma-Sect Large Loop works in conjunction with Gyrus' PlasmaKineticTM 
Tissue Management System, a revolutionary new technology providing high levels
of pulsed radio frequency (RF) energy.



Mr. Alan C. Eaton of the Queen Elizabeth Hospital, King's Lynn, Norfolk, UK said
the new device would "allow more men to take advantage of day surgery."



"The standard surgical treatment requires inpatient care for 2 to 7 days whereas
the Gyrus system allows physicians to treat men on a day-case or outpatient
basis," said Mr. Eaton.  "As the numbers of hospital beds decrease men could
find themselves waiting for long periods of time for relief from this condition.
  Utilization of the system has other advantages such as reduced blood loss and
it operates in a safe saline environment instead of traditional glycine the
absorption of which can lead to hyponatremia. This can be a potentially serious
complication where the patient can become confused, anxious and convulsive."



Mr. Eaton has recently completed a comprehensive prospective study published in
the April edition of the British Journal of Urology International**.  The
objective was to evaluate the potential for providing elective transurethral
prostatectomy on a day-case basis using Gyrus PlasmaKinetic technology.  Forty
men with confirmed bladder outlet obstruction caused by benign prostatic
enlargement underwent PlasmaKinetic vaporization of the prostate (PKVP) in the
Day Surgery Unit at the Queen Elizabeth Hospital.   All were scheduled to be
discharged the day of surgery with an indwelling catheter, returning for a trial
removal of the catheter at 48 hours and follow up at 2 and 4 months after
surgery.



The results showed that 34 of the 40 patients were able to return home on the
day of the surgery.  All patients, including the six who could not return home
the same day, felt the procedure helped relieve their symptoms.



"My conclusion is that PKVP effectively relieves prostatic obstruction and can
be safely delivered on a day-case basis," added Mr. Eaton.


The new device, developed and manufactured at Gyrus Medical Ltd. in Cardiff and
distributed in the U.S. by Gyrus Medical Inc. is part of the division's complete
system for urology.  The system is designed to tackle the surgical challenges of
removing excess tissue while working close to key anatomic structures around the
prostate and bladder.



Ends



About Gyrus

Gyrus Group PLC is a growing medical technology company based in Reading, UK.
The Group comprises four operational units: Gyrus Medical Inc. Gyrus Medical
Ltd., Gyrus International Ltd. and Gyrus ENT.





Enquiries:


Gyrus Group PLC
Christian Williams, Director of Corporate Communications               Tel: 01189 219720

Financial Dynamics                                                     Tel: 0207 831 3113
Edward Bridges/Sarah Manners



BACKGROUND AND MARKET UPDATE



Urologic applications for Plasma-SectTM  Large Loop



The 4.0 mm loop is designed to remove larger amounts of tissue during Saline
Transurethral Resection (TURP).  This is the same proven plasma technology that
has helped urologists worldwide bloodlessly vaporize unwanted tissue.  The
system gives surgeons the advantage of faster removal of larger prostates,
controlled haemostasis (less blood loss), reduced time in the operating room and
faster patient discharge.



Gyrus Medical's Plasma-Sect system is the first and only dual-function device
available to urologists that allows both controlled resection with
microvaporization and tissue sealing around the entire loop.  This effectively
eliminates the need for multiple instrument exchanges and thereby reduces time
in the operating room.



The system offers urologists an entire line of instruments to vaporize, seal,
resect, enucleate or incise prostate tissue.



The unique radio frequency energy source of the PlasmaKineticTM  Tissue
Management System powers the new Plasma-Sect Large Loop.  The system provides
controlled, consistent energy delivery which minimizes thermal spread (burning
and charring) to patient tissue.



The procedures address in excess of 15 million potential patients. However it
has been initially focussed on a subset of  men who may have failed medical
treatment and/or have a larger prostate gland by the time of surgical
intervention, a niche market valued at approximately $50 million.



**British Journal of Urology International (2002), 89, 534-537





                      This information is provided by RNS
            The company news service from the London Stock Exchange

Gyg (LSE:GYG)
Historical Stock Chart
Von Jun 2024 bis Jul 2024

Gyg (LSE:GYG)
Historical Stock Chart
Von Jul 2023 bis Jul 2024